Cobimetinib | Search results | NICE

Showing 1 to 3 of 3 results for cobimetinib

Sort by

Cobimetinib in combination with vemurafenib for treating unresectable or metastatic BRAF V600 mutation-positive melanoma (TA414)
Evidence-based recommendations on cobimetinib (Cotellic) with vemurafenib (Zelboraf) for treating unresectable or metastatic melanoma in adults with a BRAF V600 mutation.
Result type
Technology appraisal guidance
Published
26 October 2016
View recommendations for TA414
Show all sections
Sections for TA414
Atezolizumab with cobimetinib for untreated BRAF wild-type metastatic melanoma [ID1470]
Discontinued Reference number: GID-TA10354
Result type
Technology appraisal guidance
Status
Discontinued
Atezolizumab with cobimetinib and vemurafenib for treating unresectable or metastatic BRAF V600 mutation-positive melanoma [ID1674]
Discontinued Reference number: GID-TA10543
Result type
Technology appraisal guidance
Status
Discontinued